OR WAIT null SECS
April 13, 2026
Article
Although the approval does not permit entrance into the market, this decision marks an important step to more universally accessible GLP-1 RAs.
April 11, 2026
Video
Nissen discusses his post-hoc analysis of the SURPASS-CVOT trial, comparing the 2 drugs for a 6-component composite endpoint of cardiorenal outcomes.
April 09, 2026
Catch up on FDA decisions, new GLP-1 agonists, and more.
March 2026 endocrinology updates include key FDA approvals, advances in diabetes and obesity therapies, and innovations in insulin delivery and rare disease care.
April 04, 2026
Podcast
This episode covers the March 26th approval of Awiqli for T2D, highlighting its high concentration and once-weekly administration.
April 03, 2026
This episode discusses the recently released algorithm for T2D from the American Association of Clinical Endocrinology.
April 01, 2026
Hosts break down the latest updates in mineralocorticoid receptor agonists, including the SPIRIT-HF trial and announcements from the finerenone program.
March 31, 2026
Laurel Messer, PhD, RN, joins the show to provide insight into the latest updates from Tandem Diabetes Care.
March 30, 2026
REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.
Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.
